<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604669</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00004573</org_study_id>
    <secondary_id>e4573</secondary_id>
    <nct_id>NCT00604669</nct_id>
  </id_info>
  <brief_title>TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients</brief_title>
  <official_title>Total Parenteral Nutrition(TPN)-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A growing body of evidence suggests hyperglycemia is associated with adverse outcomes in
      patients with and without diabetes. Observational studies document an association between
      hyperglycemia and poor clinical outcomes in cardiothoracic surgery, elective surgery,
      myocardial infarction, stroke. Randomized studies indicate glycemic control is associated
      with improved outcomes in diabetic patients with critically illness. Hyperglycemia is a
      recognized and common complication of patients receiving total parenteral nutrition (TPN).
      Few studies in the literature have looked into the impact of TPN-associated inhospital
      complications and mortality. Accordingly, this study aims to evaluate the impact of
      hyperglycemia on clinical outcome (infections, systemic sepsis, cardiac complications, acute
      renal failure, length of stay, and mortality) in patients receiving TPN. We will perform a
      retrospective chart review of all patients treated with TPN from 1/01/06 to 12/31/06 at Grady
      Memorial Hospital. We hypothesize that patients receiving TPN who develop hyperglycemia
      experience higher morbidity (infections, systemic sepsis, cardiac complications, acute renal
      failure, length of stay) and mortality compared to TPN patients with euglycemia. The results
      of this study will help us to formulate a prospective randomized clinical trial on the
      management of TPN-associated hyperglycemia in hospitalized patients.

      This study aims to evaluate the impact of hyperglycemia on clinical outcome (infections,
      systemic sepsis, cardiac complications, acute renal failure, length of stay, in hospital
      mortality) in patients receiving total parenteral nutrition. We will perform a retrospective
      chart review of all patients admitted to the hospital receiving TPN from 1/01/06 to 12/31/06
      at Grady Memorial Hospital. The results of this study will help us to formulate a prospective
      randomized clinical trial on the management of TPN-associated hyperglycemia in hospitalized
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotheses:

      We hypothesize that patients receiving TPN who develop hyperglycemia experience higher
      morbidity (infections, systemic sepsis, cardiac complications, acute renal failure, length of
      stay) and mortality compared to TPN patients with euglycemia.

      Specific Aim:

      To determine the impact of hyperglycemia on clinical outcome (infection, systemic sepsis,
      cardiac complications, acute renal failure, length of stay, mortality) in patients receiving
      total parenteral nutrition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>at the end of the chart review of all patients</time_frame>
    <description>Mortality rate of those with hyperglycemia while on TPN duing the period of 1/01/06 to 12/31/06.</description>
  </primary_outcome>
  <enrollment type="Actual">170</enrollment>
  <condition>Hyperglycemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving TPN at Grady Memorial Hospital during the period of 1/01/06 to
        12/31/06.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Perform a retrospective chart analysis of all patients receiving TPN at
        Grady Memorial Hospital during the period of 1/01/06 to 12/31/06.

        Exclusion criteria: None except for charts without adequate data sufficient for chart
        review.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>December 8, 2008</results_first_submitted>
  <results_first_submitted_qc>March 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2010</results_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Nutrition/Dietics</keyword>
  <keyword>clinical outcomes</keyword>
  <keyword>total parenteral nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>170 charts reviewed</recruitment_details>
      <pre_assignment_details>Nothing to disclose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Those Exposed to TPN</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>lack of information in chart</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Those Exposed to TPN</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="163"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mortality</title>
        <description>Mortality rate of those with hyperglycemia while on TPN duing the period of 1/01/06 to 12/31/06.</description>
        <time_frame>at the end of the chart review of all patients</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Those Exposed to TPN</title>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Mortality rate of those with hyperglycemia while on TPN duing the period of 1/01/06 to 12/31/06.</description>
          <units>mortality rate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Those Exposed to TPN</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

